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Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary syndromes and/or undergo-
ing percutaneous coronary interventions. Clopidogrel, in combination with aspirin, is currently the antiplatelet
treatment of choice for prevention of stent thrombosis, and clinical trials have shown that, in high-risk patients,
prolonged dual antiplatelet treatment is more effective than aspirin alone in preventing major cardiovascular
events. However, despite the use of clopidogrel, a considerable number of patients continue to have cardiovas-
cular events. Numerous in vitro studies have shown that individual responsiveness to clopidogrel is not uniform
in all patients and is subject to inter- and intraindividual variability. Notably, there is a growing degree of evi-
dence that recurrence of ischemic complications may be attributed to poor response to clopidogrel. The mecha-
nisms leading to poor clopidogrel effects are not fully elucidated and are likely multifactorial. Although the gold
standard definition to assess antiplatelet drug response has not been fully established, there is sufficient evi-
dence to support that persistence of enhanced platelet reactivity despite the use of clopidogrel is a clinically rel-
evant entity. This paper reviews the impact of individual response variability to clopidogrel on clinical outcomes
and current and future directions for its management. (J Am Coll Cardiol 2007;49:1505–16) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.044p
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clatelets play a key role in the pathophysiology of thrombosis
fter plaque rupture (1). Plaque rupture occurs spontaneously
n patients with acute coronary syndromes (ACS), or may be
atrogenically induced in patients undergoing percutaneous
oronary interventions (PCI). Among the multiple media-
ors of platelet activation, adenosine diphosphate (ADP)
lays a pivotal role. Adenosine diphosphate binds to several
eceptors on the platelet membrane (2). Thienopyridines are
rreversible inhibitors of the ADP P2Y12 receptor. Ticlopi-
ine is a first-generation thienopyridine, which, in combi-
ation with aspirin, has shown to be beneficial and superior
o oral anticoagulants in preventing thrombotic complica-
ions after coronary stenting (3–6). Today clopidogrel, a
econd-generation thienopyridine with similar efficacy, has
argely replaced ticlopidine due to its better tolerability
rofiles (7) and is currently the antiplatelet treatment of
hoice for prevention of stent thrombosis (8). In addition, in
rom the *Division of Cardiology, University of Florida-Shands Jacksonville, Jack-
onville, Florida; and the †Cardiovascular Institute, San Carlos University Hospital,
adrid, Spain. Dr. Angiolillo is on the speakers’ bureau and is a consultant for
anofi-Aventis and Bristol-Myers Squibb.t
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006, accepted November 28, 2006.atients undergoing PCI, prolonged dual antiplatelet ther-
py has been associated with better long-term clinical
utcomes (9,10). The long-term clinical benefit associated
ith dual antiplatelet therapy has been observed overall in
atients with unstable angina and non–ST-segment eleva-
ion myocardial infarction (STEMI) independent of coro-
ary revascularization (11). More recently, the spectrum of
linical benefit of clopidogrel has also been extended to
atients with STEMI (12,13).
Despite the unambiguous clinical benefit achieved with
he adjunct of clopidogrel in ACS/PCI patients, a consid-
rable number of patients continue to have cardiovascular
vents. This has been, in part, attributed to the fact than
ome patients may have poor clopidogrel-induced antiplate-
et effects. These patients, in fact, despite treatment with
lopidogrel, persist with enhanced platelet reactivity, which
s pivotal for the development of atherothrombotic compli-
ations (1). Although the mechanisms leading to poor
lopidogrel effects are not fully elucidated and the best
efinition to assess antiplatelet drug response has not been
ully established, there is sufficient evidence to support that
ersistence of enhanced platelet reactivity despite the use of
lopidogrel is a clinically relevant entity. This paper reviews
he impact of individual response variability to clopidogrel
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Clopidogrel Response Variability April 10, 2007:1505–16on clinical outcomes and current
and future directions for its
management.
ADP Receptors
and Mechanism of
Action of Clopidogrel
Adenosine diphosphate is one of
the most important mediators of
both physiological hemostasis and
thrombosis (2). After platelet acti-
vation, ADP is not only released
from its intracellular storage gran-
ules but also further activates
platelets, amplifying this process.
There are 2 main purinergic recep-
tor types in the membrane: the
guanosine triphosphate (GTP)-
coupled protein receptors, known
as G-protein binding sites, and the
ligand-gated ion channel (2). The
latter receptor is designated P2X1
and the former is designated as
P2Y, and each play a specific and
complimentary role in platelet ac-
tivation and aggregation (Fig. 1).
The P2X1 utilizes adenosine
triphosphate (ATP) as an agonist
and mediates extracellular cal-
cium influx leading to alteration
n platelet shape. There are 2 known P2Y receptors: P2Y1
nd P2Y12, which utilize ADP as an agonist. Activation of
he P2Y1 receptor leads to a series of signaling events that
nitiate a weak and transient phase of platelet aggregation.
n particular, P2Y1 is coupled to a Gq protein, and its
ntracellular signaling pathways involve activation of phos-
holipase C resulting in diacylglycerol and inositol triphos-
hate production. Diacylglycerol activates protein kinase C,
hich leads to phosphorylation of myosin light chain kinase
nd granule secretion; inositol triphosphate leads to mobi-
ization of intracellular calcium. The P2Y1 receptor is
oupled to another G-protein, G12, which activates the
Rho” protein and is believed to lead to change in platelet
hape. Activation of the P2Y12 receptor leads to a complex
eries of intracellular signaling events that result in activa-
ion of the glycoprotein (GP) IIb/IIIa receptor, granule
elease, amplification of platelet aggregation, and stabiliza-
ion of the platelet aggregate. The P2Y12 receptor is coupled
o a Gi protein and its intracellular signaling pathways
nvolve activation of phosphoinositide-3-kinase and inhibi-
ion of adenylyl cyclase. Phosphoinositide-3-kinase activa-
ion leads to GP IIb/IIIa activation through activation of a
erine-threonine protein kinase B and of Rap1b GTP-
inding proteins. Inhibition of adenylyl cyclase decreases
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ADP  adenosine
diphosphate
ATP  adenosine
triphosphate
cAMP  cyclic adenosine
monophosphate
CYP  cytochrome P450
GP  glycoprotein
GTP  guanosine
triphosphate
LTA  light transmittance
aggregometry
MFI  median fluorescence
intensity
NSTE-ACS  non–ST-
segment elevation acute
coronary syndrome
PCI  percutaneous
coronary intervention
PGE1  prostaglandin E1
STEMI  ST-segment
elevation myocardial
infarction
VASP-P  vasodilator-
stimulated phosphoprotein-
phosphorylationyclic adenosine monophosphate (cAMP) levels. Reduction rf cAMP levels influences the activity of cAMP-dependent
rotein kinases that, in turn, reduce cAMP-mediated phos-
horylation (P) of vasodilator-stimulated phosphoprotein
VASP) and eliminate its protective effect on GP IIb/IIIa
eceptor activation (Fig. 1).
Clopidogrel selectively and irreversibly inhibits the P2Y12
eceptor (14). Clopidogrel is an inactive pro-drug that
equires oxidation by the hepatic cytochrome P450 (CYP)
ystem to generate an active metabolite. However, 85% of
he pro-drug is hydrolyzed by esterases in the blood to an
nactive carboxylic acid derivative, and only 15% of the
ro-drug is metabolized by the CYP system in the liver to
enerate an active metabolite. In particular, the thiophene
ing of clopidogrel is oxidized to form an intermediate
etabolite (2-oxo-clopidogrel), which is further oxidized,
esulting in the opening of the thiophene ring and the
ormation of a carboxyl and thiol group. The reactive thiol
roup of the active metabolite of clopidogrel forms a
isulfide bridge between 1 or more cysteine residues of the
2Y12 receptor, resulting in its irreversible blockade for the
ife span of the platelet. Thus, P2Y12 receptor blockade acts
arly in the cascade of events leading to the formation of the
latelet thrombus and effectively inhibits platelet aggrega-
ion. In fact, platelet P2Y12 blockade prevents platelet
egranulation and the release reaction, which elaborates
rothrombotic and inflammatory mediators from the plate-
et, and also inhibits the transformation of the GP IIb/IIIa
eceptor to the form that binds fibrinogen and links platelets
Fig. 1).
latelet Function Testing
everal methods have been used to assess clopidogrel-induced
ntiplatelet effects (15) (Table 1). However, none of these tests
ave been fully standardized or fully agreed upon to measure
lopidogrel responsiveness. Turbidometric light transmittance
ggregometry (LTA) using ADP as an agonist is currently
onsidered the gold standard technique to assess clopidogrel
esponse. Although most investigations have used this
echnique to assess clopidogrel response variability, several
efinitions of poor clopidogrel response have been adopted.
n addition, LTA may be subject to several methodological
ariables that may also lead to variances in the prevalence of
oor responders. These may include the dose of agonist (5
r 20 mol/l), the nature of the anticoagulant (citrate or
irudin/PPACK), and the LTA value (maximal or late
latelet aggregation), among many other variables, used for
he assessment (16,17). In addition to these methodological
ariables, LTA is time-consuming, technically demanding,
nd not available in most centers, limiting its broad scale
pplication.
Defining clopidogrel-induced antiplatelet effects using
TA is also confounded by the fact that although clopi-
ogrel prevents ADP from inducing platelet activation
hrough inhibition of the P2Y12 receptor, the other ADP
eceptor subtypes can still be activated and contribute to the
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April 10, 2007:1505–16 Clopidogrel Response Variabilitynal degree of platelet aggregation (2). This has led to the
evelopment of assays more specific to the P2Y12 pathway.
low cytometric assessment of VASP-P is a marker of
2Y12 receptor reactivity and, thus, clopidogrel-induced
nhibition (18). It uses 2 different agonists: prostaglandin E1
PGE1) and ADP. Prostaglandin E1 increases VASP-P
evels by stimulation of adenylate cyclase. Binding of ADP
o P2Y12 leads to Gi-coupled inhibition of adenylate cyclase.
herefore, the addition of ADP to PGE1-stimulated plate-
ets reduces PGE1-induced VASP-P levels. If P2Y12 recep-
ors are successfully inhibited by clopidogrel, addition of
DP will not reduce the PGE1-stimulated VASP-P
evels. Assessing median fluorescence intensity (MFI) of
ASP-P levels using this approach has allowed the
Figure 1 P2 Receptors and Mechanism of Action of Clopidogre
Clopidogrel is a pro-drug administered orally. Approximately 85% of the pro-drug is
15% of the pro-drug is metabolized by the cytochrome P450 (CYP) system in the li
adenosine diphosphate (ADP) P2Y12 receptor. Activation of the P2X1 and P2Y1 rec
aggregation. The P2X1 mediates extracellular calcium influx and utilizes adenosine
leads to activation of phospholipase C (PLC), which generates diacylglycerol (DAG)
glycerol activates protein kinase C (PKC) leading to phosphorylation of myosin ligh
receptor is coupled to another G-protein, G12, which activates the “Rho” protein a
P2Y12 receptor liberates the Gi protein subunits i and  and results in stabilizat
which reduces cyclic adenosine monophosphate (cAMP) levels. This, in turn, dimin
(VASP-P). The status of VASP-P modulates glycoprotein (GP) IIb/IIIa receptor activa
GP IIb/IIIa receptor activation through activation of a serine-threonine protein kinas
AC, which increases cAMP levels and status of VASP-P. Solid arrows  activation;efinition of the P2Y12 reactivity ratio, which is calculated es follows: ([MFI PGE1]  [MFI PGE1  ADP]/[MFI
GE1])  100%. A reduced P2Y12 reactivity ratio is
ndicative of more enhanced clopidogrel-induced inhibition.
nother advantage of the VASP assay is that samples can be
xed and shipped to central core laboratories for its assess-
ent. This allows to overcome the technical limitations that
any centers may have in performing these highly specific
ssays. Nevertheless, this does not overcome the need for
apid, widely available, and reliable bedside measures of
latelet aggregation.
The VerifyNow P2Y12 point-of-care assay (Accumetrics,
an Diego, California) has been recently approved by the
ood and Drug Administration. This is a user-friendly
ystem that rapidly measures in whole blood the rate and
yzed by esterases in the blood to an inactive carboxylic acid derivative, and only
generate an active metabolite. The active metabolite irreversibly inhibits the
leads to alteration in shape and initiates a weak and transient phase of platelet
sphate (ATP) as an agonist. The binding of ADP to the Gq-coupled P2Y1 receptor
ositol triphosphate (IP3) from phosphatidylinositol bisphosphate (PIP2). Diacyl-
kinase (MLCK-P); IP3 leads to mobilization of intracellular calcium. The P2Y1
elieved to lead to change in platelet shape. The binding of ADP to the Gi-coupled
platelet aggregation. The i subunit leads to inhibition of adenylyl cyclase (AC),
cAMP-mediated phosphorylation of vasodilator-stimulated phosphoprotein (VASP)
he subunit  activates the phosphatidylinositol 3-kinase (PI3K), which leads to
KB/Akt) and of Rap1b GTP binding proteins. Prostaglandin E1 (PGE1) activates
d arrows  inhibition.l
hydrol
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dottextent of platelet aggregation (19). In particular, it performs
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Clopidogrel Response Variability April 10, 2007:1505–16turbidimetric measurement of agglutination of platelets to
brinogen-coated micro-beads. This assay applies a similar
rinciple to that used by the VASP platelet assay in order to
pecifically evaluate inhibition of the P2Y12 pathway as it
ses a combination of ADP and PGE1 as agonists in order
o increase the specificity of the test. In addition, a separate
ell containing thrombin receptor activating peptide
TRAP) provides a baseline platelet function assessment,
llowing the measurement of the degree of platelet inhibi-
ion in patients on clopidogrel without having to wean the
atient off clopidogrel. Given their broad availability and
imple-to-use characteristics, similar assays are more prac-
ical in the clinical setting and have a promising role in the
uture for guiding antiplatelet treatment. Ongoing studies
re currently evaluating the clinical risk of patients based on
he results of such point-of-care assays.
efinition of Clopidogrel Responsiveness
tandardized definitions to define individual responsiveness
o clopidogrel are still lacking. This is due not only to the
umerous assays currently available to assess clopidogrel-
nduced antiplatelet effects but also to the methodological
ariability within each technique (i.e., LTA). Light trans-
ittance aggregometry has been most extensively evaluated
o define clopidogrel responsiveness, and several definitions
o define clopidogrel responsiveness have been used. Earlier
tudies have defined clopidogrel responsiveness according to
he absolute differences between pre- and post-treatment
latelet reactivity (20); other studies have defined clopi-
ogrel responsiveness according to the degree of inhibition
f platelet aggregation or IPA, defined as the percent
ecrease in aggregation values obtained at baseline and after
reatment (21). These studies have shown clopidogrel-
nduced antiplatelet effect to be highly variable and that a
onsiderable number of patients may have poor or no
ntiplatelet effects. Using an arbitrary cutoff value of 10%
ith the respective definitions, these ex-vivo platelet func-
ion studies have thus led to define these individuals with
latelet Function Tests Assessingdenosine Diphospha e Rec ptor Antagonism
Table 1 Platelet Function Tests AssessingAdenosine Diphosphate Receptor Antagonism
Platelet aggregation
Turbidometric light transmittance aggregometry
Impedance platelet aggregation
Flow cytometry
GP IIb/IIIa receptor activation
P-selectin expression
Leucocyte-platelet aggregates
Vasodilator-associated stimulated phosphoprotein phosphorylation
Point-of-care
VerifyNow P2Y12 assay
Thromboelastagraph Platelet Mapping System
Plateletworks
Impact cone and plate(let) analyzer
P  glycoprotein.oor antiplatelet effects as “clopidogrel resistant” or “non-esponders.” However, subsequent investigations have em-
irically used different doses of agonists, different cutoff
alues, and different assays to define clopidogrel-induced
ntiplatelet effects resulting in a highly variable reported
revalence of poor clopidogrel responders (22,23).
Use of different nomenclature to define individuals with
neffective clopidogrel platelet inhibition, such as “low-
esponder,” “hypo-responder,” “semi-responder,” “subopti-
al responder” among others and in addition to the ones
escribed in the preceding text, has also further com-
ounded the confusion on this topic. However, the increas-
ng knowledge on the clinical impact of interindividual
ariability of clopidogrel-induced antiplatelet effects has
llowed progress in our current definitions. In fact, previous
efinitions of clopidogrel response, which imply knowledge
f baseline platelet function for its assessment, overestimate
schemic risk compared with post-treatment values of plate-
et reactivity (24). Given the better prognostic implications
f post-treatment platelet reactivity, current investigations
re now aiming to establish therapeutic thresholds to define
ptimal P2Y12 inhibition in clopidogrel-treated patients.
se of post-treatment platelet reactivity values as a measure
f effectiveness of clopidogrel effects is in line with how
ther biological variables and their response to treatment are
uantified. Accordingly, as per other biological processes,
lopidogrel responsiveness should not be considered in a
ichotomous way (25), but as a continuous and variable
arameter (Fig. 2). In the present review, we will allude to
Figure 2 Interindividual Variability in Platelet Aggregation
Platelet aggregation profile (maximal 20 mol/l ADP-induced platelet aggrega-
tion using light transmittance aggregometry) in patients (n  135) in a steady
state phase (1 month) of combined aspirin (100 mg/day) and clopidogrel (75
mg/day) therapy. Heterogeneous antiplatelet effects are observed in the over-
all patient population as depicted by the normal bell-shaped distribution of
platelet aggregation. ADP  adenosine diphosphate (D.J. Angiolillo, unpublished
data, 2006).
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April 10, 2007:1505–16 Clopidogrel Response Variabilityhe term “clopidogrel response variability” to indicate such
nterindividual variation in antiplatelet effects.
echanisms Leading to
lopidogrel Response Variability
he mechanisms leading to variability in clopidogrel re-
ponsiveness are not fully elucidated and, similarly to
spirin, are like multifactorial (Fig. 3). High pre-treatment
latelet reactivity may contribute to reduced clopidogrel-
nduced antiplatelet effects (20,22). Increased baseline plate-
et reactivity may be more commonly observed in specific
linical scenarios such as ACS, increased body mass index,
nd diabetes mellitus, in particular insulin-dependent dia-
etes mellitus (26–29). Therefore, patient selection may
nfluence the prevalence of poor clopidogrel responders in a
iven study. Other clinical factors that may lead to reduced
lopidogrel effects include lack of drug prescription, poor
ompliance, and inappropriate dosing.
Differences in individual absorption of clopidogrel as well
s levels of its active metabolite may also lead to clopidogrel
esponse variability (30). Drugs that are substrates or inhibit
he CYP isoenzyme 3A4 can potentially interfere with the
onversion of clopidogrel into its active metabolite, leading
o reduced antiplatelet effects (31). In particular, studies
ave shown that lipophilic statins, such as atorvastatin and
imvastatin, which require CYP3A4 metabolization, ham-
er clopidogrel-induced antiplatelet effects (31,32). How-
ver, these data are quite controversial as larger studies have
Figure 3 Proposed Mechanisms Leading to Variability in Individ
ADP  adenosine diphosphate; CYP  cytochrome P450; GP  glycoprotein.hown the lack of any interaction between lipophilic statins
nd clopidogrel (33–36). In addition, most studies do not
how any negative clinical interaction with coadministration
f these drugs (37). Independent of these potential drug-
rug interactions, baseline metabolic activity of this enzyme
ay also contribute to variability of clopidogrel-induced
ntiplatelet effects (38). In fact, individuals with low base-
ine CYP3A4 activity, which decreases clopidogrel activa-
ion, have been shown to have suboptimal clopidogrel
esponsiveness (38).
The metabolic activity of the CYP3A4 enzyme is under
enetic control and varies considerably among individuals
39,40). Genetic polymorphisms of this and other CYP
nzymes have been shown to modulate individual respon-
iveness to clopidogrel (39,40). The impact of other genetic
olymorphisms on clopidogrel response has also been eval-
ated. A minor haplotype of the P2Y12 receptor was found
o be associated with increased platelet reactivity in non-
edicated healthy volunteers (41). However, these findings
ould not be duplicated by several authors studying patients
ith coronary artery disease treated with clopidogrel (42–
4). Small sample size studies have shown a potential role of
enetic polymorphisms of the GP IIb/IIIa receptor on
odulation of clopidogrel response in the acute phase of
reatment (45,46). However, this has not been confirmed by
thers (44), and our group failed to replicate our initial
ndings performed in the acute phase of clopidogrel treat-
ent in patients on chronic clopidogrel therapy (47).
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Clopidogrel Response Variability April 10, 2007:1505–16verall, these findings are likely related to the fact that an
ctive metabolite, and not clopidogrel per se, is responsible
or inhibition of the P2Y12 receptor, suggesting therefore
hat an upstream target within clopidogrel’s metabolic
athway (i.e., CYP) has a more important modulating role
f its downstream antiplatelet effects (39,48,49). Recent
eports have also suggested that polymorphisms of other
argets not directly involved in clopidogrel metabolism may
e involved in response variability. These include platelet
embrane receptors, such as GP Ia, which are pivotal for
ggregatory responses (50,51).
Other mechanisms leading to variability in clopidogrel
esponsiveness may include increase exposure to ADP,
p-regulation of the P2Y12 pathway, and up-regulation of
2Y12-independent pathways (26,29,52). The latter in-
ludes enhanced ADP-induced platelet aggregation through
he P2Y1 pathway as well as up-regulation of pathways
ndependent of ADP, such as collagen, epinephrine, throm-
oxane A2, and especially thrombin.
linical Implications of Individual
esponse Variability to Clopidogrel
everal studies have shown the clinical implications of
ndividual response variability to clopidogrel. Clinical out-
omes include stent thrombosis, post-stent ischemic events,
nd periprocedural myocardial infarction. These studies
ave been performed in different subgroups of patients
ndergoing PCI, including patients with STEMI, non–ST-
egment elevation (NSTE)-ACS, and patients undergoing
lective PCI.
tent thrombosis. The first study to hypothesize the clin-
cal implications of clopidogrel responsiveness was reported
y Muller et al. (21). In this study, LTA was performed in
cohort of 105 patients undergoing PCI in which 2
ncidents of subacute stent thrombosis occurred, and both
atients were clopidogrel non-responders. Barragan et al.
53) carried out a prospective evaluation using a VASP assay
nd observed that patients experiencing subacute stent
hrombosis had significantly enhanced platelet reactivity.
jzenberg et al. (54) demonstrated that patients with
ubacute stent thrombosis have increased shear-induced
latelet aggregation compared with control subjects receiv-
ng dual antiplatelet therapy and with normal subjects
eceiving no antiplatelet therapy. The CREST (Clopidogrel
ffect on Platelet REactivity in Patients With Stent
hrombosis) study showed that high post-treatment plate-
et reactivity, assessed by LTA, and incomplete P2Y12
eceptor inhibition, assessed by VASP, were risk factors for
ubacute stent thrombosis (55).
ost-stent ischemic events and periprocedural myocar-
ial infarction. The first study suggesting the impact of
lopidogrel-induced antiplatelet effects on post-stent isch-
mic events was from Matetzky et al. (56). In this study,
atients (n  60) with STEMI undergoing primary PCI
ere stratified into 4 quartiles according to the percentage teduction of ADP-induced platelet aggregation using LTA.
hereas 40% of patients in the first quartile sustained a
ecurrent cardiovascular event (STEMI, ACS, subacute
tent thrombosis, and acute peripheral arterial occlusion)
uring 6-month follow-up, only 1 patient (6.7%) in the
econd quartile and none in the third and fourth quartiles
uffered a cardiovascular event (p  0.007). Cuisset et al.
57) studied a series of 106 NSTE-ACS patients treated
ith PCI in whom LTA was assessed at the time of
ntervention; in this series 12 ischemic events occurred at
-month follow-up, of which 9 occurred in the highest
ggregation quartile and 3 in the second highest quartile.
ecently, the same authors also showed that in NSTE-ACS
atients (n  292) undergoing coronary stenting, the use of
600-mg clopidogrel loading dose reduced the number of
atients with high post-treatment platelet reactivity com-
ared with a standard 300-mg loading dose regimen, which
lso resulted in improved clinical outcomes (58).
The largest prospective study supporting the prognostic
mplications of platelet function measures is the EXCELSIOR
Impact of Extent of Clopidogrel-Induced Platelet Inhibi-
ion During Elective Stent Implantation on Clinical Event
ate) study (59). In this study, a cohort of relatively low-risk
atients (n  802) undergoing elective coronary stenting
re-treated at least 2 h before intervention with a 600-mg
oading dose of clopidogrel was evaluated. Patients showing
igher degrees of “late” 5 mol/l ADP-induced platelet
ggregation assessed by LTA immediately “before” inter-
ention (those in the 2 upper quartiles) suffered more
requently 30-day major adverse cardiac events, which
ccurred in 15 patients. Notably, platelet aggregation above
he absolute median value of the study population (14% of
ggregation) carried a 6.7-fold risk of events. Furthermore,
n multivariate logistic regression models (including all poten-
ial confounders such as baseline platelet aggregation and time
rom clopidogrel loading to intervention) platelet aggregation
merged as an independent predictor of early clinical outcome.
The CLEAR PLATELETS (Clopidogrel Loading with
ptifibatide to Arrest PLATELET reactivity) and CLEAR
LATELETS Ib studies showed that in patients (n  120)
ndergoing elective PCI, a 600-mg loading dose of clopi-
ogrel was associated with superior early platelet inhibition
ompared with a 300-mg loading dose (60,61). This en-
anced platelet inhibition was sustained over 24 h and was
ccompanied by a decrease in release of myocardial necrosis
nd inflammatory markers. Gurbel et al. (62) also showed in
he PREPARE POST-STENTING (Platelet REactivity
n Patients And Recurrent Events POST-STENTING)
tudy, that higher degrees of “maximal” 20 mol/l ADP-
nduced platelet aggregation assessed by LTA “at discharge”
as associated with ischemic events (63 12% vs. 56 15%,
 0.02) at 6 months in patients (n  192) undergoing
on-emergent stenting. All patients were treated with a
oading dose of clopidogrel (300 or 600 mg) “after” inter-
ention. Notably, 90% of patients with events had post-
reatment platelet reactivity values above 50%. In line with
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April 10, 2007:1505–16 Clopidogrel Response Variabilityhe prognostic implications of high post-treatment platelet
eactivity after acute clopidogrel administration, even pa-
ients on chronic clopidogrel therapy undergoing non-
mergent PCI, those who exhibit high on-treatment ADP-
nduced platelet aggregation are at increased risk for post-
rocedural ischemic events up to 6 months (63).
Lev et al. (64) evaluated response to clopidogrel using
TA in aspirin-resistant and -sensitive patients (n  150)
ndergoing elective PCI. Aspirin-resistant patients had
ower response to clopidogrel than aspirin-sensitive patients
nd50% of aspirin-resistant patients were also resistant to
lopidogrel. Elevation of cardiac enzymes after stenting
ccurred more frequently in aspirin-resistant (12.7%) versus
spirin-sensitive patients and in clopidogrel-resistant (24%)
ersus clopidogrel-sensitive patients. Patients with dual
rug resistance had higher incidence of cardiac enzyme
levation than the respective sensitive patients (44.4% vs.
5.8%; p  0.05).
Geisler et al. (65) assessed responsiveness to clopidogrel
sing LTA in a total of 379 consecutive patients (stable
ngina n 206 and ACS n 173) undergoing PCI treated
ith a 600-mg loading dose. At 3-month follow-up, the
rimary outcome of a combined major cardiovascular event
ncluding nonfatal myocardial infarction, non-fatal ischemic
troke, or cardiovascular death showed that low responders
5.8%) had a significantly higher risk of major cardiovascular
vents compared with patients who adequately responded to
lopidogrel (22.7% vs. 5.6%; odds ratio 4.9; p 0.004). After
djustment for other factors influencing cardiovascular out-
ome, low response to clopidogrel and severe left ventricular
ysfunction were independently associated with a major car-
iovascular event within 3 months (hazard ratio for low
esponse to clopidogrel 3.71; p  0.037).
anagement of Patients
ith Poor Clopidogrel Response
ariability in clopidogrel-induced antiplatelet effects has
ecome an emerging clinical entity with potentially severe
onsequences (66). Therefore, it becomes imperative to
uestion how a clinician can effectively manage this phe-
omenon. Unfortunately, not only the definition but also
ow to treat these patients remains undefined. An initial
pproach would be to correct the clinical factors that may be
eading to poor responsiveness. Importantly, physicians
ust ensure proper patient compliance. Albeit controversial,
ecreasing drug–drug interactions (e.g., CYP3A4 metabo-
izing statins) may potentially optimize response. Since
bnormal lipid, glucose, and blood pressure levels may lead
o abnormalities of the platelet plasmatic membrane and
latelet dysfunction, their control may enable better re-
ponse to antiplatelet agents.
Several studies have focused on the impact of the loading
ose of clopidogrel utilized in patients undergoing PCI and
ave clearly defined underdosing as a pivotal cause to poor
esponsiveness. In fact, although a 300-mg loading dose is ahe standard loading dose regimen to be given in patients
ndergoing PCI, several functional studies have shown that
600-mg loading dose leads to an earlier, stronger, and
ore sustained inhibition of platelet function (23,67). Using
600-mg loading dose regimen, full antiplatelet effects are
chieved after 2 h (68). Furthermore, a high loading dose
egimen may also prevent the reduction of platelet inhibi-
ion by concomitant use of statins metabolized by CYP3A4
34,36). The ARMYDA-2 (Antiplatelet therapy for Reduc-
ion of MYocardial Damage during Angioplasty-2) study
howed the benefit of pre-treatment with a 600-mg loading
ose when compared with 300-mg in reducing periproce-
ural myocardial infarction in patients undergoing PCI,
ithout any increase in bleeding hazards (69). Similar
utcome results have been recently replicated by the Cuisset
t al. (58) study, in which improved clinical outcomes were
lso corroborated by better platelet inhibition with a high
oading dose regimen.
Despite these studies supporting the functional and
linical impact of a high loading dose regimen and its broad
pplication in daily clinical practice by most interventional-
sts, these are overall small sample size studies, and the use
f a 600-mg loading dose regimen has still not been cleared
y the Food and Drug Administration. The ongoing
URRENT/OASIS-7 (Clopidogrel optimal loading dose
sage to Reduce Recurrent EveNTs/Optimal Antiplatelet
trategy for InterventionS) trial will evaluate whether high-
ose clopidogrel achieves better clinical outcomes than
tandard dose in14,000 NSTE-ACS patients undergoing
CI. Patients randomized to the high dose will receive a
00-mg loading dose then 150-mg daily maintenance dose
rom day 2 to day 7; patients randomized to the standard
ose will receive a 300-mg loading dose then 75-mg daily
aintenance dose from day 2 to day 7; from day 8 to day 30,
ll patients will receive clopidogrel 75 mg daily. In addition,
ll patients will get randomized to receive aspirin low dose
75 to 100 mg) or high dose (300 to 325 mg); regardless of
andomized allocation to high- or low-dose aspirin, all
atients will receive aspirin 300 mg on day 1. Other
ngoing studies evaluating a 600-mg clopidogrel loading
ose regimen include ARMYDA-4, which will determine
he clinical benefit of a further loading dose of 600-mg
lopidogrel pre-PCI in patients already on chronic treat-
ent, and ARMYDA-5, which will assess clinical outcomes
f patients undergoing PCI with a pre-loading strategy of
00-mg clopidogrel 4 to 8 h before PCI versus in-lab
dministration of a 600-mg loading dose after coronary
ngiography, immediately pre-PCI. The latter will address a
ighly debated issue in daily clinical practice, which is the
roblem of knowing coronary anatomy before giving the drug.
The utility of increasing the loading dose of clopidogrel
o 900 mg has been recently evaluated in the ALBION
Assessment of the Best Loading Dose of Clopidogrel to
lunt Platelet Activation, Inflammation, and Ongoing
ecrosis) and the ISAR-CHOICE (Intracoronary Stentingnd Antithrombotic Regimen: Choose Between 3 High
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Clopidogrel Response Variability April 10, 2007:1505–16ral Doses for Immediate Clopidogrel Effect) trials (70,71).
lthough a high loading dose regimen (600 mg and 900
g) showed a greater and faster degree of platelet inhibition
ompared with a 300-mg loading dose, the differences
bserved between a 600- and 900-mg loading regimen were
ess remarkable. Therefore, although clopidogrel response is
ose-dependent, there is a threshold to its platelet inhibitory
ffects when certain doses are reached. This supports the
eed for the adjunctive use of a GP IIb/IIIa inhibitor in
atients with poor clopidogrel response and in whom more
otent platelet inhibition is warranted (60,72). In line with
his observation, the CLEAR-PLATELETS study showed
hat the use of a GP IIb/IIIa inhibitor produces superior
latelet inhibition resulting in lower myocardial necrosis
ompared with high (600-mg) or standard (300-mg) clopi-
ogrel loading dose alone (60).
Recently, it was shown that the administration of a
00-mg loading dose in patients already on chronic clopi-
ogrel therapy results in an additional significant increase in
nhibition of ADP-induced platelet aggregation, suggesting
hat the current recommended maintenance dose of clopi-
ogrel may be insufficient in producing optimal platelet
nhibition (73). The currently used maintenance dose for
hronic clopidogrel therapy (75 mg/day) was chosen because
degree of platelet inhibition is reached similar to that
chieved with ticlopidine 250 mg twice daily (74). There-
ore, it has been suggested that increasing the maintenance
ose to 150 mg/day may improve individual responsiveness
o clopidogrel in selected patient populations. The ISAR-
HOICE-2 (Intracoronary Stenting and Antithrombotic
egimen: Choose a High Oral maintenance dose for
ntensified Clopidogrel Effect) showed that in an unselected
ohort of patients a 150-mg maintenance dose resulted in
nhanced platelet inhibition compared with a standard
5-mg maintenance dose regimen 1 month after undergo-
ng low-risk PCI (75). The OPTIMUS (Optimizing anti-
latelet Therapy In diabetes MellitUS) study selectively
tudied diabetes mellitus patients with high post-treatment
latelet reactivity while in their chronic phase of treatment
76). In these patients, although a 150-mg clopidogrel
aintenance dose resulted in marked platelet inhibition of
umerous platelet function measures compared with a
5-mg dose, a considerable number of patients still re-
ovel P2Y12 Receptor Antagonists Under Phase III Clinical Investig
Table 2 Novel P2Y12 Receptor Antagonists Under Phase III Clin
Drug Type Administration Acti
Prasugrel (CS-747) Thienopyridine
(3rd generation)
Oral Requires hepat
to generate a
metabolite
Irreversible bind
AZD-6140 Cyclopentyl-triazolo-
pyrimidine
Oral Direct inhibition
Competitive bin
Cangrelor
(ARC-669931MX)
ATP analogue Parenteral Direct inhibition
Competitive binTP  adenosine triphosphate; CHAMPION  Cangrelor versus Standard Therapy to Achieve Optimal Ma
nd Patient Outcomes; TRITON  Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pained above the therapeutic threshold of post-treatment
latelet reactivity used in this study, suggesting the need for
ore potent P2Y12 inhibitors or alternative antithombotic
egimens in these high-risk patients. However, studies
ufficiently powered to assess safety and clinical impact are
arranted before using platelet function testing and adjust-
ent of antithrombotic drug regimens in clinical practice.
urrent guidelines state (class IIb indication with a level of
vidence C) that only patients in whom stent thrombosis
ay be catastrophic or lethal (unprotected left main, bifur-
ating left main, and last patent coronary vessel) may the
ose of clopidogrel be increased to 150 mg per day if 50%
nhibition of platelet aggregation is demonstrated (8).
Although higher loading and maintenance doses of clo-
idogrel improve responsiveness, there is still a broad inter-
nd intravariability in the degree of antiplatelet effects
chieved. In addition, results from the PREPARE POST-
TENTING study show that 50% of ischemic events
ccur in patients with post-treatment platelet reactivity
ithin the 25th and 75th percentile distribution. These
bservations are suggestive that other thrombotic factors
i.e., thrombin generation), and not just platelet reactivity,
ay also play an important role in determining atherothrom-
otic events. This supports that inhibition of targets other than
yclooxygenase-1 and P2Y12, in particular thrombin, need to
e evaluated to reduce thrombotic risk (62).
uture Directions
he current therapeutic alternative for treatment of patients
ith poor clopidogrel response remains limited. Novel
2Y12 receptor antagonists with more potent antiplatelet
ffects are currently under clinical investigation (77). These
ovel molecules are all characterized by more potent anti-
latelet effects, reduced interindividual response variability,
nd therefore less likely to lead to resistance. Novel P2Y12
eceptor antagonists under clinical investigation include
rasugrel, AZD6140, and cangrelor (Table 2).
Prasugrel (CS-747) is a member of the thienopyridine
lass of oral antiplatelet agents (78). Like ticlopidine and
lopidogrel, prasugrel (a third-generation thienopyridine) is
pro-drug and needs to be transformed in the liver into an
ctive metabolite. The active metabolite of prasugrel, like
Investigation
Dose
Mean Platelet Inhibition
(Time Required)
Trial
(Phase III)
ersion 60-mg loading dose,
10-mg maintenance
dose
	70% (1 h) TRITON
90 mg/twice daily 	95% (2–4 h) PLATO
4 g/kg/min 	95% (few minutes) CHAMPIONation
ical
on
ic conv
ctive
ing
ding
dingnagement of Platelet Inhibition; CYP  cytochrome P450; PLATO  A Study of Platelet Inhibition
latelet Inhibition With Prasugrel.
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April 10, 2007:1505–16 Clopidogrel Response Variabilityhe active metabolite of clopidogrel, leads to selective and
rreversible blockade of the P2Y12 receptor. However, com-
ared with clopidogrel, prasugrel is more efficiently trans-
ormed into its active metabolite (79). A single oral admin-
stration of prasugrel produces a dose-related inhibition of
latelet aggregation in rats approximately 10- and 100-fold
ore potent than that of clopidogrel and ticlopidine,
espectively. Better degrees of platelet inhibition have also
een confirmed in patients with coronary artery disease (80).
he antiaggregatory effects of prasugrel are evident at 30
in and last until 72 h after dosing, indicating fast onset
nd long duration of action. The results of the JUMBO–
IMI (Joint Utilization of Medications to Block Platelets
ptimally–Thrombolysis In Myocardial Infarction)-26
hase II trial showed that prasugrel has safety profiles
significant, non-coronary artery bypass grafting, bleeding
hrough 30 days—primary end point of the study) compa-
able to standard-dose clopidogrel in patients (n  900)
ndergoing PCI (81). Albeit not powered to assess clinical
nd points, encouraging clinical outcomes were observed in
his trial. The ongoing TRITON (Trial to Assess Improve-
ent in Therapeutic Outcomes by Optimizing Platelet
nhibition With Prasugrel)–TIMI-38 phase III trial will
ompare prasugrel and clopidogrel in over 13,000 patients
ith ACS undergoing PCI with the primary end point of
eath, myocardial infarction, and stroke at 12 months. An
dditional study, the PRINCIPLE (Prasugrel in Compar-
son to Clopidogrel for Inhibition of Platelet Activation and
ggregation)–TIMI-44, is currently comparing the relative
otency of prasugrel with a higher loading dose (600 mg)
nd maintenance dose (150 mg daily) of clopidogrel by
ssessing measures of platelet function, inflammation, and
yocyte necrosis in patients undergoing elective PCI.
AZD6140 is the first oral reversible ADP receptor
ntagonist. It is a non-thienopyridine that belongs to a new
hemical class called cyclopentyl-triazolo-pyrimidine.
ZD6140 does not require hepatic metabolism for its
ctivity and directly inhibits the P2Y12 receptor (82). Plate-
et aggregation studies have shown that AZD6140 blocks
latelet reactivity more consistently and completely than
lopidogrel with a lower degree of interindividual response
ariability (83). The DISPERSE 2 (Safety, Tolerability and
reliminary Efficacy of AZD6140, the First Oral Reversible
DP Receptor Antagonist, Compared with Clopidogrel in
atients with Non–ST-Segment Elevation Acute Coronary
yndrome) was a phase II trial comparing AZD6140 with
lopidogrel in patients (n  990) with ACS that showed
imilar rates of bleeding in all groups (primary end point:
otal major/minor bleeding events at 4 weeks) and no
ignificant difference in the composite end point of cardio-
ascular death, stroke, or recurrent ischemia (84). The
ngoing PLATO (A Study of Platelet Inhibition and
atient Outcomes) phase III clinical trial is comparing
ZD6140 and clopidogrel in ACS patients with the pri-
ary end point of death, myocardial infarction, and stroket 12 months. dCangrelor (also known as AR-C69931MX) is also a
elective and competitive P2Y12 antagonist, which is suit-
ble for intravenous administration (85). Cangrelor is an
TP analogue, with more potent antiplatelet activity than
lopidogrel (90% inhibition of platelet aggregation at 1 to 4
g/kg/min intravenous) that leads to selective inhibition of
DP-induced aggregation in a dose-dependent manner.
mportantly, there is a rapid reversal of its dose-dependent
ffects. Reports from phase II clinical trials show that
angrelor in addition to tissue-type plasminogen activator in
atients with STEMI is associated with a greater degree of
T-segment recovery in a dose-dependent manner (85).
urther, in patients undergoing PCI, cangrelor compares
avorably with abciximab both from a safety and clinical
tandpoint. Two phase III trials with cangrelor (CHAM-
ION PCI and CHAMPION PLATFORM) are currently
ngoing.
These novel and more potent P2Y12 ADP receptor
ntagonists may have advantages over currently available
ntiplatelet agents, which are likely related to the increased
egree of platelet inhibition (77). Increased platelet reactiv-
ty, in fact, is an important predictor of ischemic events.
owever, increased platelet inhibition not necessarily trans-
ates into better safety profiles as more potent antiplatelet
gents may increase hemorrhagic risk. Results from phase
II clinical trials will provide more definitive answers on the
isk/benefits of these agents. Pre-clinical investigation of
ther ADP receptor antagonist such as INS-50589 (a
inucleotide intended for intravenous administration) and
T-50547 (a benzothiazolothiadiazine intended for oral
dministration) is also undergoing and will further nurture
his evolving field of research with the goal of identifying
he optimal treatment of patients with atherothrombotic
isease undergoing PCI (77).
onclusions
oor responsiveness to antiplatelet agents, including clopi-
ogrel, is an emerging clinical entity. Although there is
ncreasing evidence that monitoring the effects of antiplate-
et therapy may allow identification of patients at an
ncreased risk of developing ischemic events, current clinical
uidelines do not support routine screening for antiplatelet
rug resistance. This is, in part, because the definition of the
ost appropriate platelet function assay has not been
stablished and because of the lack of clinical trials showing
he impact on clinical outcomes of treatment modification
n patients resistant to antiplatelet agents. Currently, the
ost accurate platelet function assays are expensive, time-
onsuming, and not broadly available. Therefore, rapid and
ccurate diagnosis of responsiveness to antiplatelet agents
lso remains an issue. Widespread clinical application of
ssessment of antiplatelet drug response will require studies
n large populations that define responsiveness in a stan-
ardized manner using assays with consistency and repro-
ucibility, which correlate the measurements with clinical
o
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Clopidogrel Response Variability April 10, 2007:1505–16utcomes, and that provide the strategies for modifying
ntiplatelet regimens to improve outcomes. Such tailored
reatment regimens according to individual’s need (through
ntensification or reduction of antithrombotic medication)
ill potentially reduce ischemic as well as bleeding risk in
atients with hypo- and hyper-response, respectively, to
tandard treatment regimens. Defining the mechanisms
eading to variability in responsiveness to antiplatelet agents,
he best diagnostic tool for its evaluation, and the therapeu-
ic measures for its treatment will hopefully set the future
asis for routine measurements of platelet function and a
ew era of individualized antithombotic regimens (86).
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